The company
Ascendis Pharma A/S - Ordinary Share
ASND · Nasdaq
ASND stood above a rising 150-day average in 45 of the last 52 weekly readings, and has been out of that trend for the last 5 weeks. It is 6.4% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).
Statistics
- Rotation
- Not moving yet
- Weeks in an uptrend
- out for 5
- Industry in uptrend
- 15% -17 in 4 wk
- Insider buys, 12 months
- $1.6M
- Insider sales, 12 months
- $11.0M
- Officials’ trades on record
- 3
- Institutions holding
- 292 (+34)
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 45 of 52 weeks.
Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.
Money in and out
Open-market buys above the line and sales below, in dollars.
Congress and officials
3 disclosed lines: House 3, Senate 0, executive 0; 1 people.
| Who | Did | Amount | Traded |
|---|---|---|---|
| Gary J. Palmer House: U.S. House ClerkAL06 | sold | $1k–$15k | 5 Oct 2018filed 7 Nov 2018 |
| Gary J. Palmer House: U.S. House ClerkAL06 | bought | $1k–$15k | 6 Aug 2018filed 29 Sep 2018 |
| Gary J. Palmer House: U.S. House ClerkAL06 | boughtjoint | $1k–$15k | 12 Jul 2018filed 29 Sep 2018 |
Insiders
| Who | Did | Shares | Traded |
|---|---|---|---|
| Mads BodenhoffSVP & PAO | sold | 3,000at $270.19 | 8 Sep 2026filed 9 Sep 2026 |
| Lars HoltugDirector | sold | 236at $264.13 | 2 Sep 2026filed 3 Sep 2026 |
| Jean Jacques BienaimeDirector | bought | 1,100at $245.85 | 14 Aug 2026filed 18 Aug 2026 |
| Jean Jacques BienaimeDirector | bought | 900at $246.91 | 14 Aug 2026filed 18 Aug 2026 |
| Scott Thomas SmithEVP & Chief Financial Officer | bought | 100at $219.00 | 2 Jun 2026filed 2 Jun 2026 |
| Scott Thomas SmithEVP & Chief Financial Officer | bought | 250at $223.32 | 29 May 2026filed 1 Jun 2026 |
| Jean Jacques BienaimeDirector | bought | 200at $223.76 | 29 May 2026filed 1 Jun 2026 |
| Jean Jacques BienaimeDirector | bought | 200at $222.30 | 29 May 2026filed 1 Jun 2026 |
| Jean Jacques BienaimeDirector | bought | 100at $223.50 | 29 May 2026filed 1 Jun 2026 |
| Jean Jacques BienaimeDirector | bought | 200at $236.24 | 26 May 2026filed 27 May 2026 |
| Jean Jacques BienaimeDirector | bought | 200at $239.37 | 26 May 2026filed 27 May 2026 |
| Flemming Steen JensenOfficer | sold | 19,460at $238.49 | 11 May 2026filed 12 May 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|---|---|
| RA CAPITAL MANAGEMENT, L.P.unchanged · filed 14 Aug 2026 | 10,281,496$2.7B | 00.0% |
| Avoro Capital Advisors LLCadded · filed 14 Aug 2026 | 5,111,111$1.4B | +48,611+1.0% |
| WESTFIELD CAPITAL MANAGEMENT CO LPreduced · filed 12 Aug 2026 | 4,798,267$1.3B | -15,173−0.3% |
| Jupiter Topco LLCnew · filed 14 Aug 2026 | 3,648,772$973.4M | +3,648,772 |
| FMR LLCreduced · filed 13 Aug 2026 | 3,545,575$945.7M | -331,026−8.5% |
| Artisan Partners Limited Partnershipreduced · filed 13 Aug 2026 | 2,634,024$702.5M | -596,164−18.5% |
| BlackRock, Inc.added · filed 7 Aug 2026 | 2,211,833$589.9M | +1,550,779+234.6% |
| Capital International Investorsadded · filed 12 Aug 2026 | 1,988,614$530.4M | +29,771+1.5% |
| MASSACHUSETTS FINANCIAL SERVICES COadded · filed 3 Aug 2026 | 1,875,301$500.1M | +14,632+0.8% |
| FRANKLIN RESOURCES INCreduced · filed 13 Aug 2026 | 1,862,503$496.8M | -189,445−9.2% |
News
No headline names it lately.
Everyone who traded it
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.